Oct 24 (Reuters) – Eli Lilly and Company: * LILLY PRESENTS FIRST CLINICAL DATA IN PLATINUM-SENSITIVE OVARIAN CANCER FOR ITS INVESTIGATIONAL, NEXT-GENERATION, FRΑ-TARGETING ADC AT ESMO 2026 * ELI LILLY
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate…
Marquez wins thrilling Australian MotoGP sprint to retake championship lead
VIDEO SHOWS: HIGHLIGHTS OF THE AUSTRALIA MOTOGP QUALIFYING AND SPRINT RACE TEMPLATE ONLY, SHOTLIST AND…
DANGER HAS PASSED IN JEDDAH – SAUDI CIVIL DEFENSE
DANGER HAS PASSED IN JEDDAH - SAUDI CIVIL DEFENSE (The article has been published through…
